| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
160,760,000 |
| Market
Cap: |
2.69(B) |
| Last
Volume: |
1,167,639 |
Avg
Vol: |
1,642,843 |
| 52
Week Range: |
$16.31 - $33.465 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Acadia Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system disorders. Co. has a portfolio of product including its drug, NUPLAZID (pimavanserin), which has been approved by the U.S. Food and Drug Administration for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. NUPLAZID is a selective serotonin inverse agonist/antagonist, targeting 5-HT2A receptors with no appreciable affinity for dopaminergic, histaminergic, or muscarinic receptors.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
896,522 |
896,522 |
| Total Buy Value |
$0 |
$0 |
$22,707,098 |
$22,707,098 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
3 |
3 |
| Total Shares Sold |
69,383 |
88,489 |
392,894 |
447,814 |
| Total Sell Value |
$1,291,363 |
$1,772,230 |
$9,596,766 |
$10,578,437 |
| Total People Sold |
4 |
5 |
6 |
7 |
| Total Sell Transactions |
11 |
18 |
34 |
57 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Schneyer Mark C. |
EVP, Chief Financial Officer |
• – – |
2023-06-08 |
4 |
S |
$25.02 |
$24,369 |
D/D |
(974) |
22,824 |
|
7% |
|
| Schneyer Mark C. |
EVP, Chief Financial Officer |
• – – |
2023-06-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,893 |
23,798 |
|
- |
|
| Soland Daniel B |
Director |
– • – |
2023-06-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,552 |
28,002 |
|
- |
|
| Harrigan Edmund |
Director |
– • – |
2023-06-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,552 |
19,002 |
|
- |
|
| Daly James M |
Director |
– • – |
2023-06-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,552 |
18,002 |
|
- |
|
| Baker Brothers Life Sciences Lp |
Director |
– • • |
2023-06-01 |
4 |
A |
$0.00 |
$0 |
I/I |
26,608 |
39,330,977 |
|
- |
|
| Brege Laura |
Director |
– • – |
2023-06-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,552 |
18,002 |
|
- |
|
| Garofalo Elizabeth A. |
Director |
– • – |
2023-06-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,552 |
18,780 |
|
- |
|
| Baker Brothers Life Sciences Lp |
Director |
– • • |
2023-05-24 |
4 |
B |
$25.27 |
$14,096,825 |
I/I |
553,263 |
39,317,673 |
2.25 |
-19% |
|
| Baker Brothers Life Sciences Lp |
Director |
– • • |
2023-05-23 |
4 |
B |
$25.33 |
$5,312,458 |
I/I |
209,053 |
38,811,515 |
2.25 |
-16% |
|
| Baker Brothers Life Sciences Lp |
Director |
– • • |
2023-05-23 |
4 |
OE |
$17.01 |
$425,250 |
I/I |
25,000 |
38,620,261 |
|
- |
|
| Baker Brothers Life Sciences Lp |
Director |
– • • |
2023-05-22 |
4 |
B |
$24.46 |
$3,297,815 |
I/I |
134,206 |
38,607,761 |
2.25 |
-16% |
|
| Teehan Brendan |
EVP, COO, Head of Commercial |
• – – |
2023-05-17 |
4 |
S |
$22.50 |
$334,553 |
D/D |
(14,869) |
24,356 |
|
-4% |
|
| Teehan Brendan |
EVP, COO, Head of Commercial |
• – – |
2023-05-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
29,738 |
39,225 |
|
- |
|
| Schneyer Mark C. |
EVP, Chief Financial Officer |
• – – |
2023-05-17 |
4 |
S |
$22.50 |
$344,475 |
D/D |
(15,310) |
21,905 |
|
-4% |
|
| Schneyer Mark C. |
EVP, Chief Financial Officer |
• – – |
2023-05-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
29,738 |
37,215 |
|
- |
|
| Kihara James |
Principal Accounting Officer |
• – – |
2023-05-17 |
4 |
S |
$22.50 |
$133,808 |
D/D |
(5,947) |
11,144 |
|
-4% |
|
| Kihara James |
Principal Accounting Officer |
• – – |
2023-05-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,894 |
17,091 |
|
- |
|
| Teehan Brendan |
EVP, COO, Head of Commercial |
• – – |
2023-05-01 |
4 |
S |
$21.18 |
$11,607 |
D/D |
(548) |
9,487 |
|
-22% |
|
| Davis Stephen |
CEO |
• • – |
2023-05-01 |
4 |
S |
$21.18 |
$165,331 |
D/D |
(7,806) |
108,297 |
|
-22% |
|
| Kim Austin D. |
EVP,General Counsel, Secretary |
• – – |
2023-05-01 |
4 |
S |
$21.18 |
$19,422 |
D/D |
(917) |
25,513 |
|
-22% |
|
| Teehan Brendan |
EVP, COO, Head of Commercial |
• – – |
2023-04-29 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,567 |
10,035 |
|
- |
|
| Davis Stephen |
CEO |
• • – |
2023-04-29 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,625 |
116,103 |
|
- |
|
| Kim Austin D. |
EVP,General Counsel, Secretary |
• – – |
2023-04-29 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,005 |
26,430 |
|
- |
|
| Kihara James |
Principal Accounting Officer |
• – – |
2023-04-10 |
4 |
S |
$18.14 |
$9,487 |
D/D |
(523) |
5,197 |
|
-62% |
|
634 Records found
|
|
Page 3 of 26 |
|
|
0.40 (2.45%) 
